Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise

Pamidronate is a bisphosphonate derivative that can inhibit bone resorption by actions on osteoclasts and increase bone density in spite of treatment with steroids. This drug has the anti-inflammatory effect by increase apoptosis of monocytes. 5-10 percent of rheumatoid arthritis patients is seroneg...

Descripción completa

Detalles Bibliográficos
Autores principales: Salesi, Mansour, Mottaghi, Peyman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications Pvt Ltd 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214385/
https://www.ncbi.nlm.nih.gov/pubmed/22091296
_version_ 1782216251435646976
author Salesi, Mansour
Mottaghi, Peyman
author_facet Salesi, Mansour
Mottaghi, Peyman
author_sort Salesi, Mansour
collection PubMed
description Pamidronate is a bisphosphonate derivative that can inhibit bone resorption by actions on osteoclasts and increase bone density in spite of treatment with steroids. This drug has the anti-inflammatory effect by increase apoptosis of monocytes. 5-10 percent of rheumatoid arthritis patients is seronegative and may be resistant to conventional disease modifying anti rheumatic drugs (DMARDs). Intravenous (IV) pamidronate can be effective in disease control in seronegative rheumatoid arthritis. We report two cases of seronegative and drug resistant rheumatoid arthritis that favorably responds to pamidronate.
format Online
Article
Text
id pubmed-3214385
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-32143852011-11-16 Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise Salesi, Mansour Mottaghi, Peyman J Res Med Sci Case Report Pamidronate is a bisphosphonate derivative that can inhibit bone resorption by actions on osteoclasts and increase bone density in spite of treatment with steroids. This drug has the anti-inflammatory effect by increase apoptosis of monocytes. 5-10 percent of rheumatoid arthritis patients is seronegative and may be resistant to conventional disease modifying anti rheumatic drugs (DMARDs). Intravenous (IV) pamidronate can be effective in disease control in seronegative rheumatoid arthritis. We report two cases of seronegative and drug resistant rheumatoid arthritis that favorably responds to pamidronate. Medknow Publications Pvt Ltd 2011-05 /pmc/articles/PMC3214385/ /pubmed/22091296 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Salesi, Mansour
Mottaghi, Peyman
Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title_full Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title_fullStr Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title_full_unstemmed Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title_short Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
title_sort pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214385/
https://www.ncbi.nlm.nih.gov/pubmed/22091296
work_keys_str_mv AT salesimansour pamidronateinfusionimprovedtwocasesofintractableseronegativerheumatoidarthritise
AT mottaghipeyman pamidronateinfusionimprovedtwocasesofintractableseronegativerheumatoidarthritise

Ejemplares similares